226 related articles for article (PubMed ID: 19712172)
1. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs.
Santagostino E; Morfini M; Auerswald GK; Benson GM; Salek SZ; Lambert T; Salaj P; Jimenez-Yuste V; Ljung RC
Haemophilia; 2009 Sep; 15(5):983-9. PubMed ID: 19712172
[TBL] [Abstract][Full Text] [Related]
2. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
[TBL] [Abstract][Full Text] [Related]
3. Prevention of haemophilic arthropathy in haemophilic children with inhibitors.
Rodriguez-Merchan EC
Haemophilia; 2008 Nov; 14 Suppl 6():1-3. PubMed ID: 19134025
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
5. Some recent developments regarding arthropathy and inhibitors in haemophilia.
Rodriguez-Merchan EC
Haemophilia; 2008 Mar; 14(2):242-7. PubMed ID: 18201189
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA
Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
[TBL] [Abstract][Full Text] [Related]
7. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
Valentino LA
Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors.
Leissinger CA; Becton DL; Ewing NP; Valentino LA
Haemophilia; 2007 May; 13(3):249-55. PubMed ID: 17498073
[TBL] [Abstract][Full Text] [Related]
9. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis in haemophilia with inhibitors: update from international experience.
Carcao M; Lambert T
Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
[TBL] [Abstract][Full Text] [Related]
11. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
12. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
Szmurło D; Deryło Ł; Ryś P; Władysiuk M
Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
[TBL] [Abstract][Full Text] [Related]
14. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
Valentino LA
Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis in haemophilia patients with inhibitors.
Leissinger CA
Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
[TBL] [Abstract][Full Text] [Related]
16. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
17. When should prophylaxis therapy in inhibitor patients be considered?
Young G; Auerswald G; Jimenez-Yuste V; Konkle BA; Lambert T; Morfini M; Santagostino E; Blanchette V
Haemophilia; 2011 Sep; 17(5):e849-57. PubMed ID: 21418444
[TBL] [Abstract][Full Text] [Related]
18. Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.
Šalek SZ; Auerswald G; Benson G; Dolan G; Duffy A; Hermans C; Jiménez-Yuste V; Ljung R; Morfini M; Santagostino E; Lambert T
Blood Transfus; 2017 Jan; 15(1):77-84. PubMed ID: 26674816
[TBL] [Abstract][Full Text] [Related]
19. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.
Morfini M; Auerswald G; Kobelt RA; Rivolta GF; Rodriguez-Martorell J; Scaraggi FA; Altisent C; Blatny J; Borel-Derlon A; Rossi V
Haemophilia; 2007 Sep; 13(5):502-7. PubMed ID: 17880436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
